From sponsor-initiated clinical trials to observational cohort studies and investigator-initiated research programs, VIDC makes strides in scientific advancement while providing access to treatment for marginalized and vulnerable populations.
The overall mission of the VIDC clinical research team is to understand and advance the knowledge of HCV and HIV transmission, infection, prevention and re-infection to recognize how these impact population-level demographics and prevalence. Our research team presents their findings regularly at forums and conferences both nationally and internationally.
The team obtains funding through grants to support community initiatives such as community pop-up clinics, HIV sexual health promotion workshops and weekly patient support groups.
This study is a randomized, quadruple masked, interventional study. The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people living with HIV (PLWH) with multi-drug resistance (MDR).
This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC) of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with human immunodeficiency virus type 1 (HIV-1) infection.
The purpose of the CANUHC research study is to collect and study information on all types of people living with Hepatitis C, including subjects with cirrhosis (advanced scarring of liver), the elderly, people who inject drugs, among others.
Newer, all-oral, pan-genotypic direct-acting antiviral (DAA) lead to a cure of infection in > 95% of Hepatitis C virus (HCV) cases. Although these well-tolerated, highly effective treatments are widely available to all viremic patients in British Columbia, significant barriers undermine our ability to increase HCV treatment starts, especially in vulnerable inner-city populations.
CoCo (CTN 222)
The Canadian Co-infection Cohort study follows a group of HIV and Hepatitis C (HCV) co-infected patients from 18 centres across Canada. The primary objective of this study is to determine the effect of antiretroviral therapy (ART) on liver disease progression in HIV-HCV co-infection.
The Grand Plan study is an open label study. The purpose is to determine the effectiveness of providing a multidisciplinary care approach to initiating glecaprevir/Pibrentasvir tablets (G/P) for eight weeks in treating HCV infection.
This is a Phase 2 study to evaluate response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucelos(t)ide analog regimen with or without pegylated interferon alpha-2a in Immune Tolerant patients with Chronic Hepatitis B Infection.